Paper Details

  1. Home
  2. Paper Details

Multiple myeloma treated with mitoxantrone in combination with vincristine and prednisolone (NOP regimen) versus melphalan and prednisolone: a phase III study. Nordic Myeloma Study Group (NMSG).

Author: BjerrumO W, DahlI M, DrivsholmA, EllegaardJ, GadebergO, GimsingP, GrønvoldT, HansenM M, HippeE, KeldsenN

Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Clinical Trial, Phase IIIA Phase III trial is a trial that further rigorously verifies the efficacy and safety of a new drug or treatment, whose efficacy and safety have been confirmed in a Phase II trial, in a large number of patients, and evaluates whether it is superior to existing treatments.
Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Controlled Clinical TrialA clinical trial that evaluates the effectiveness of a treatment by comparing a group that receives the intervention with a group that receives a placebo or standard treatment.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

A study of 151 patients with multiple myeloma compared two treatment regimens: NOP (mitoxantrone, vincristine, prednisolone) and M+P (melphalan, prednisolone). While both regimens achieved similar response rates (60% for NOP, 64% for M+P), the time to progression was longer for M+P (21 months vs. 16 months) and median survival was significantly longer for the M+P group (31 months vs. 14 months). NOP was significantly more toxic, with 7 deaths due to infection and neutropenia and one death from cardiac toxicity compared to one death from infection and neutropenia in the M+P group. The study concluded that M+P is superior to NOP as primary treatment for multiple myeloma.
Paper Details　
Original Abstract of the Article :
One-hundred-and-fifty-one patients with previously untreated multiple myeloma were allocated to treatment with either NOP regimen (mitoxantrone 16 mg/m2 and vincristine 2 mg day 1 and prednisolone 250 mg day 1-4 and 17-20) or M+P regimen (melphalan 0.25 mg/kg and prednisolone 100-200 mg/day day 1-4)...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1111/j.1600-0609.1993.tb01597.x

データ提供：米国国立医学図書館（NLM）

Multiple Myeloma: Navigating the Desert of Treatment Options

Multiple myeloma is a serious blood cancer that requires aggressive treatment strategies. This research compares two different chemotherapy regimens for multiple myeloma: NOP (mitoxantrone, vincristine, and prednisolone) and M+P (melphalan and prednisolone). The authors conduct a phase III clinical trial to evaluate the efficacy and safety of these regimens in patients with previously untreated multiple myeloma.

The Quest for Effective Treatment: Comparing Regimens in the Desert of Multiple Myeloma

This research reveals important insights into the effectiveness and safety of two chemotherapy regimens for multiple myeloma. The authors demonstrate that while both regimens showed similar response rates, the NOP regimen was associated with significantly higher toxicity, including a higher risk of infection, neutropenia, and cardiac toxicity. These findings highlight the importance of carefully considering the risks and benefits of different treatment options when managing multiple myeloma.

Navigating the Complexities of Multiple Myeloma: A Guide to Treatment Strategies

This research underscores the importance of choosing the most appropriate treatment regimen for patients with multiple myeloma, balancing efficacy with safety. The authors' findings suggest that while the NOP regimen may offer some advantages in terms of response rate, it is associated with greater toxicity. This research emphasizes the need for personalized treatment plans tailored to individual patient characteristics and risk factors.

Dr.Camel's Conclusion

This research highlights the importance of carefully considering the risks and benefits of different treatment options when managing multiple myeloma. The authors' findings suggest that the NOP regimen, while offering similar response rates to M+P, is associated with significantly higher toxicity. This research emphasizes the need for individualized treatment plans tailored to individual patient characteristics and risk factors.
Date :
  1. Date Completed 1993-10-13
  2. Date Revised 2019-09-09
Further Info :

Pubmed ID

8370422

DOI: Digital Object Identifier

10.1111/j.1600-0609.1993.tb01597.x

Related Literature

Article Analysis
・Effective treatment of multiple myeloma
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.